Thus, although genetic-driven tumour profiling is similar to that of IPF-free LC, as documented by EGFR behaviour and asset, the immune tumour status should be strictly related to the surrounding IPF stroma and the clinicopathologic features of the interstitial diseases. This evidence concerns the gene EGFR and idiopathic pulmonary fibrosis.